IC
APLS

Ikarian Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Ikarian Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200,000
Closed -$5.77M – 176
2024
Q3 		$5.77M Buy
+200,000
New +$7.41M 0.8% 31
2024
Q2 		– Sell
-100,000
Closed -$5.88M – 118
2024
Q1 		$5.88M Buy
+100,000
New +$6.37M 0.64% 49
2023
Q4 		– Sell
-412
Closed -$1.57M – 142
2023
Q3 		$1.57M Sell
412
-132,588
-100% -$5.82M 0.19% 84
2023
Q2 		$12.1M Buy
+133,000
New +$11.5M 1.93% 12
2021
Q4 		– Sell
-345,400
Closed -$11.4M – 190
2021
Q3 		$11.4M Buy
345,400
+45,400
+15% +$2.55M 0.8% 32
2021
Q2 		$19M Buy
+300,000
New +$15.5M 1.53% 13
2020
Q1 		– Sell
-286,900
Closed -$8.79M – 156
2019
Q4 		$8.79M Buy
+286,900
New +$7.94M 1.42% 20

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ikarian Capital's APLS Position: Q1 2026 in Review

Ikarian Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 71,747 shares — an estimated $1.8M sold.

Ikarian Capital first reported a position in APLS in Q4 2019 and held it in 15 quarters. The position peaked at $12.2M in Q2 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Ikarian Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 71,747 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.8M.
  • Ikarian Capital first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 15 quarters.
  • Ikarian Capital's Apellis Pharmaceuticals position peaked at $12.2M in Q2 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.